We are live on ! Find out more
CAM

Cormorant Asset Management Portfolio holdings

AUM $1.95B
1-Year Est. Return 773.9%
This Fund
S&P 500
This Quarter Est. Return
-11.26%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$742M
AUM Growth
-$165M
Cap. Flow
-$34.2M
Cap. Flow %
-4.61%
Top 10 Hldgs %
45.48%
Holding
92
New
8
Increased
13
Reduced
17
Closed
15

Top Buys

Rank Stock Value
1
KA
Kineta, Inc. Common Stock
KA
+$16.9M
2
BPMC
Blueprint Medicines
BPMC
+$16.4M
3
TBPH icon
Theravance Biopharma
TBPH
+$9.51M
4
NVRO
NEVRO CORP.
NVRO
+$9.42M
5
SGYP
Synergy Pharmaceuticals, Inc Common Stock
SGYP
+$7.84M

Top Sells

Rank Stock Value
1
CLVS
Clovis Oncology, Inc.
CLVS
+$23.4M
2
MGNX icon
MacroGenics
MGNX
+$21.2M
3
CLLS
Cellectis
CLLS
+$12M
4
ADXS
Advaxis Inc
ADXS
+$9.85M
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$8.55M

Sector Composition

Rank Sector Weight
1 Healthcare 99.94%
2 Miscellaneous 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RGNX icon
51
Regenxbio
RGNX
$519M
$2.91M 0.39%
156,741
– –
ATXS
52
DELISTED
Astria Therapeutics
ATXS
$2.89M 0.39%
13,333
– –
CRVS icon
53
Corvus Pharmaceuticals
CRVS
$1.05B
$2.84M 0.38%
198,526
-15,606
-7% -$237K
LPCN icon
54
Lipocine
LPCN
$18.2M
$2.77M 0.37%
44,194
– –
XNCR icon
55
Xencor
XNCR
$1.79B
$2.63M 0.35%
+100,000
New +$2.4M
OTLK icon
56
Outlook Therapeutics
OTLK
$166M
$2.51M 0.34%
5,208
-1,212
-19% -$678K
NGNE icon
57
Neurogene
NGNE
$677M
$2.51M 0.34%
7,592
– –
ABEO icon
58
Abeona Therapeutics
ABEO
$304M
$2.42M 0.33%
+20,000
New +$3.13M
AVXS
59
DELISTED
AveXis, Inc. Common Stock
AVXS
$2.39M 0.32%
49,991
-81,867
-62% -$4.37M
IMDZ
60
DELISTED
Immune Design Corp.
IMDZ
$2.38M 0.32%
432,990
– –
SGMO
61
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$1.98M 0.27%
650,000
-752,331
-54% -$2.74M
EPZM
62
DELISTED
Epizyme, Inc
EPZM
$1.93M 0.26%
159,513
– –
TIG
63
DELISTED
TiGenix American Depositary Shares
TIG
$1.88M 0.25%
+129,032
New +$1.87M
CBIO
64
Crescent Biopharma
CBIO
$655M
$1.75M 0.24%
2,870
– –
SNDX icon
65
Syndax Pharmaceuticals
SNDX
$1.58B
$1.72M 0.23%
240,403
– –
APTO
66
DELISTED
Aptose Biosciences, Inc.
APTO
$1.38M 0.19%
2,201
– –
MYOV
67
DELISTED
Myovant Sciences Ltd.
MYOV
$1.24M 0.17%
+100,000
New +$1.16M
NSTG
68
DELISTED
NanoString Technologies, Inc.
NSTG
$903K 0.12%
40,490
– –
AVEO
69
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$587K 0.08%
108,772
– –
HTGM
70
DELISTED
HTG Molecular Diagnostics, Inc. Common Stock
HTGM
$456K 0.06%
1,130
– –
MTEM
71
DELISTED
Molecular Templates, Inc.
MTEM
$446K 0.06%
6,135
– –
ONSIZ
72
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$329K 0.04%
416,666
– –
NEOS
73
DELISTED
Neos Therapeutics, Inc
NEOS
$296K 0.04%
50,613
– –
AGTC
74
DELISTED
Applied Genetic Technologies Corporation
AGTC
$162K 0.02%
17,321
– –
ONSIW
75
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$79K 0.01%
416,666
– –
1 2
3
4

Similar funds

AHC
Adell Harriman & Carpenter Houston, Texas $1.95B AUM 52.72% 1-Year Est. Return
FFS
Founders Financial Securities Towson, Maryland $1.95B AUM 22.17% 1-Year Est. Return
GIP
Granite Investment Partners El Segundo, California $1.95B AUM 49.89% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.95B AUM 25.88% 1-Year Est. Return
BFPW
BOK Financial Private Wealth Denver, Colorado $1.95B AUM 20.52% 1-Year Est. Return
MSA
MUFG Securities Americas New York $1.95B AUM 42.71% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return
GF
Greenhouse Funds Baltimore, Maryland $1.96B AUM 36.47% 1-Year Est. Return

Cormorant Asset Management's Q4 2016 Portfolio in Review

As of Q4 2016, Cormorant Asset Management held 92 positions worth $742M, down 18% from $907M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Cormorant Asset Management withdrew a net $34.2M in Q4 2016, closing 15 positions and reducing 17 holdings. Its most notable exit was Clovis Oncology, Inc., an estimated $23.4M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, Cormorant Asset Management opened a new position in Synergy Pharmaceuticals, Inc Common Stock worth $9.13M.

  • Cormorant Asset Management's largest Q4 2016 buy was Synergy Pharmaceuticals, Inc Common Stock: 1,500,000 shares worth $9.13M.
  • Cormorant Asset Management added most to Kineta, Inc. Common Stock in Q4 2016, an estimated $16.9M increase.
  • Cormorant Asset Management's biggest Q4 2016 reduction was Omeros, cutting an estimated $7.35M.
  • Cormorant Asset Management fully exited Clovis Oncology, Inc. in Q4 2016, selling an estimated $23.4M.
  • Cormorant Asset Management's ten largest holdings make up 45% of its $742M portfolio in Q4 2016.
  • Cormorant Asset Management opened 8 new positions and closed 15 in Q4 2016.
  • Cormorant Asset Management's portfolio value fell 18% quarter-over-quarter to $742M.

Based on Cormorant Asset Management's 13F filing for Q4 2016, filed 14 Feb 2017.